Profusa Scales European Operations and Strengthens Balance Sheet Ahead of 2026 Commercial Launch
Digital health pioneer secures French distribution through MedSell, while optimizing its debt structure to fuel long-term growth and facilitate U.S. market entry.
In a pivotal year-end strategic push, Profusa (NASDAQ: PFSA) announced two major milestones that signal a shift from a clinical-stage developer to a commercial-stage digital health powerhouse. By securing a major distribution partnership in France with MedSell and successfully restructuring its senior debt, the company is clearing a path for a significant revenue ramp-up beginning in the second quarter of 2026.
Expanding the European Footprint
Profusa’s latest agreement with MedSell, a specialist in the commercialization of innovative medical devices, brings the company’s Lumee™ Oxygen tissue monitoring platform to the French healthcare market. This move completes a robust European network that already includes Spain, Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia.
The partnership is strategically significant, addressing a critical unmet need in wound care and healing clinics for patients with Chronic Limb Ischemia (CLI). With the addition of France, Profusa now reaches a market representing approximately 200,000 annual CLI cases across the European Union.
Benoit Salaün, Pharm.D., Ph.D., MedSell General Manager, stated:
“Our collaboration with Profusa stems from our particular interest in Lumee Oxygen tissue monitoring for the large population of patients in France with Critical Limb Threatening Ischemia (CLTI). The device enables the measurement of tissue oxygen perfusion before revascularization, during endovascular or open surgical procedures, and throughout follow-up in hospitals or wound care clinics.”
The distribution deal is further bolstered by Profusa’s existing collaboration with Professor Yann Gouëffic at the Groupe Hospitalier Paris Saint Joseph. Pr. Gouëffic’s practice accounts for roughly 8% of all CLTI cases in France, providing an immediate high-volume clinical anchor for the MedSell rollout.
Financial Engineering for Long-Term Value
Parallel to its commercial expansion, Profusa has moved to protect its capital structure. The company announced a major restructuring of its Senior Secured Convertible Notes, a move specifically designed to reduce share dilution and provide “repayment flexibility” as the company builds inventory for its 2026 launch.
Key changes to the financial agreement include:
- Higher Conversion Floor: The conversion floor price has been raised from $0.10 to $0.35, preventing massive share issuances at depressed prices.
- Elimination of Amortization: Mandatory cash and equity amortization payments scheduled for Q1 2026 have been removed, preserving cash for operations.
- Extended Maturity: Final payments are now deferred until the 18-month maturity mark.
“We continue to make progress restructuring our balance sheet to reduce debt and share price dilution to provide shareholders with additional value as we increase the enterprise value of the company,” said Fred Knechtel, Profusa’s CFO.
The Road to $250 Million
Under the leadership of Chairman and CEO Ben Hwang, Ph.D., Profusa has set aggressive financial targets. The company expects to generate $0.5 million to $2 million in potential revenue in 2026, scaling to $9 million to $13 million in 2027 as it targets the U.S. market. The ultimate goal is a revenue target of $200 million to $250 million by 2030.
Hwang commented:
“We are focused on executing on our commercial strategies, including plans to potentially achieve $200 to $250 million in revenue by 2030; capitalize on the near-term as we begin to commercialize in Europe in 2Q 2026 with the goal of addressing the US Lumee oxygen opportunity in 2027. We are committed to making our oxygen tissue monitoring platform easily accessible both at the clinic and at home to improve overall patient outcomes and reduce healthcare costs.”
As Profusa enters 2026, the dual focus on aggressive market entry and conservative financial management positions the company as a key player to watch in the biochemistry monitoring space.
Read Next: Why Nvidia’s Tech Investments Could Transform the Entire AI Innovation Ecosystem
Join the Discussion in the WVC Facebook Investor Group
Do you have a stock tip or news story suggestion? Please email us at: invest@wealthyvc.com.
Wealthy VC and its employees are not Registered Investment Advisors, Broker-Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Wealthy VC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Wealthy VC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Our website and newsletter are for entertainment purposes only. This website is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
Release of Liability: Through the use of this email and/or website advertisement, by viewing or using it, you agree to hold Wealthy VC, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Wealthy VC-sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Wealthy VC or an offer or solicitation to buy or sell any security.
None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Wealthy VC strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. WealthyVC and our controlling entity 1000724287 Ontario Ltd., have been compensated USD $318,000 for six months for investor relations by Profusa, Inc. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D and all reports published on SEDAR if the company featured is Canadian. Wealthy VC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors with a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day’s closing price and the high of-day price during our promotional coverage.
In preparing this publication, Wealthy VC has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, Wealthy VC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Wealthy VC is not responsible for any claims made by the companies advertised herein, nor is Wealthy VC responsible for any other promotional firm, its program or its structure.
